- Addressing the technical, cultural and policy hurdles that traditionally impede the broad access and usage of clinical trial data
- Layout a blueprint for companies to accelerate their progress in a patient-first manner
- Developing a framework to automatically approval clinical trial data requests
- Exploring the impact this has had on Novartis and the broader industry

Gabriel Eichler
Ech